Aquestive Therapeutics, Inc.
AQST
$6.46
$0.314.96%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 28.03% | 14.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.03% | 14.71% | |||
| Cost of Revenue | -1.21% | 24.89% | |||
| Gross Profit | 52.54% | 7.38% | |||
| SG&A Expenses | 20.03% | -33.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.64% | -23.91% | |||
| Operating Income | -0.98% | 41.30% | |||
| Income Before Tax | -14.01% | 40.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.01% | 40.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.01% | 40.92% | |||
| EBIT | -0.98% | 41.30% | |||
| EBITDA | -1.00% | 41.60% | |||
| EPS Basic | -2.42% | 43.19% | |||
| Normalized Basic EPS | -2.46% | 43.24% | |||
| EPS Diluted | -2.42% | 43.19% | |||
| Normalized Diluted EPS | -2.46% | 43.24% | |||
| Average Basic Shares Outstanding | 11.33% | 4.01% | |||
| Average Diluted Shares Outstanding | 11.33% | 4.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||